| scholarly article | Q13442814 |
| P2093 | author name string | Chris Feudtner | |
| Russell Localio | |||
| David Rubin | |||
| Meredith Matone | |||
| Susan dosReis | |||
| Yuan-Shung Huang | |||
| P2860 | cites work | National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. | Q51801492 |
| Trends in the Use of Typical and Atypical Antipsychotics in Children and Adolescents | Q58822795 | ||
| Current prescribing patterns in outpatient child and adolescent psychiatric practice in central New York | Q81461924 | ||
| Antipsychotic medication use among children and risk of diabetes mellitus | Q82623446 | ||
| Trends in prescribing of antipsychotic medications for US children | Q82791054 | ||
| National trends in the outpatient diagnosis and treatment of bipolar disorder in youth | Q28244462 | ||
| Monitoring and management of antipsychotic-related metabolic and endocrine adverse events in pediatric patients | Q28275063 | ||
| Predictive margins with survey data | Q30650172 | ||
| Risperidone for the treatment of affective symptoms in children with disruptive behavior disorder: a post hoc analysis of data from a 6-week, multicenter, randomized, double-blind, parallel-arm study | Q31049531 | ||
| Trends in the prescribing of psychotropic medications to preschoolers | Q33891787 | ||
| Broadened use of atypical antipsychotics: safety, effectiveness, and policy challenges. | Q33960193 | ||
| Safety of low doses of quetiapine when used for insomnia | Q34031523 | ||
| National trends in psychotropic medication polypharmacy in office-based psychiatry | Q34090959 | ||
| Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents | Q34613195 | ||
| National trends in the use of outpatient psychotherapy | Q34986143 | ||
| Psychotropic practice patterns for youth: a 10-year perspective | Q35040724 | ||
| Clinical characteristics of children receiving antipsychotic medication | Q35169629 | ||
| Antipsychotic treatment among youth in foster care | Q36071218 | ||
| Risperidone in the management of agitation and aggression associated with psychiatric disorders | Q36369066 | ||
| Atypical antipsychotic treatment of disruptive behavior disorders in children and adolescents | Q37183421 | ||
| Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents | Q37183426 | ||
| Increased prevalence of obesity and glucose intolerance in youth treated with second-generation antipsychotic medications | Q37644575 | ||
| Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: A systematic review of randomized, placebo controlled trials and guidelines for clinical practice | Q37835961 | ||
| Efficacy of atypical antipsychotic medication in the management of behaviour problems in children with intellectual disabilities and borderline intelligence: a systematic review | Q37920312 | ||
| Pediatric uptake of a newly available antipsychotic medication | Q43168370 | ||
| Effect of Medicaid eligibility category on racial disparities in the use of psychotropic medications among youths. | Q50756513 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | mental health | Q317309 |
| P304 | page(s) | 1836-1860 | |
| P577 | publication date | 2012-09-04 | |
| P1433 | published in | Health Services Research | Q5690687 |
| P1476 | title | The relationship between mental health diagnosis and treatment with second-generation antipsychotics over time: a national study of U.S. Medicaid-enrolled children | |
| P478 | volume | 47 |
| Q47258027 | Age at Exposure to Surgery and Anesthesia in Children and Association With Mental Disorder Diagnosis |
| Q92201819 | Antipsychotic Treatment Among Youths With Attention-Deficit/Hyperactivity Disorder |
| Q28287983 | Antipsychotic and psychostimulant drug combination therapy in attention deficit/hyperactivity and disruptive behavior disorders: a systematic review of efficacy and tolerability |
| Q34194447 | Antipsychotic polypharmacy in children and adolescents at discharge from psychiatric hospitalization |
| Q40386583 | Antipsychotic prescribing for behavioral disorders in US youth: physician specialty, insurance coverage, and complex regimens |
| Q36799433 | Antipsychotic treatment patterns and aggressive behavior among adolescents in residential facilities |
| Q38266796 | Clinical and pharmacokinetic evaluation of risperidone for the management of autism spectrum disorder |
| Q89505921 | Concomitant Use of Psychotropic Medication With Stimulants for the Treatment of ADHD in Children and Adolescents: A Retrospective Insurance Claims Study in the United States |
| Q37365301 | Concomitant pharmacotherapy of psychotropic medications in EU children and adolescents with attention-deficit/hyperactivity disorder |
| Q38905891 | Decrease in Statewide Antipsychotic Prescribing after Implementation of Child and Adolescent Psychiatry Consultation Services |
| Q38920204 | Examining psychotropic medication use among youth in the U.S. by race/ethnicity and psychological impairment |
| Q35809854 | Foster care, externalizing disorders, and antipsychotic use among Medicaid-enrolled youths. |
| Q38727636 | Fostering Psychotropic Medication Oversight for Children in Foster Care: A National Examination of States' Monitoring Mechanisms. |
| Q50204761 | Head-to-Head Comparison of Aripiprazole and Risperidone in the Treatment of ADHD Symptoms in Children with Autistic Spectrum Disorder and ADHD: A Pilot, Open-Label, Randomized Controlled Study |
| Q42383817 | Introducing the Best of the AcademyHealth Annual Research Meeting |
| Q40171961 | Large Disparities in Receipt of Glaucoma Care between Enrollees in Medicaid and Those with Commercial Health Insurance. |
| Q34464293 | Managing cardiovascular disease risk in patients treated with antipsychotics: a multidisciplinary approach |
| Q34580449 | Paediatric European Risperidone Studies (PERS): context, rationale, objectives, strategy, and challenges |
| Q92638901 | Patterns of treatment for psychiatric disorders among children and adolescents in Mississippi Medicaid |
| Q28295134 | Pharmacoepidemiology of antipsychotic use in youth with ADHD: trends and clinical implications |
| Q33835596 | Preliminary and ongoing French multicenter prospective naturalistic study of adverse events of antipsychotic treatment in naive children and adolescents. |
| Q53239844 | Psychotropic drug use among preschool children in the Medicaid program from 36 states. |
| Q36282556 | Quality improvement in resident education: a pilot project to mitigate metabolic side effects from atypical antipsychotic medications in youth |
| Q33769706 | Racial/ethnic differences in Medicaid expenditures on psychotropic medications among maltreated children |
| Q39027972 | Second-Generation Antipsychotic Utilization and Metabolic Parameter Monitoring in an Inpatient Pediatric Population: A Retrospective Analysis |
| Q36591575 | Second-generation antipsychotic use among stimulant-using children, by organization of medicaid mental health. |
| Q37568887 | Shooting the Messenger: The Case of ADHD. |
| Q38151774 | The comorbidity of ADHD and autism spectrum disorder |
| Q34171640 | The effects of prior authorization policies on medicaid-enrolled children's use of antipsychotic medications: evidence from two mid-Atlantic states |
| Q30698390 | Use of antipsychotic medications in pediatric populations: what do the data say? |
| Q38953538 | Use of psychotropic drugs in patients with autism spectrum disorders: a systematic review |
Search more.